Metabolic syndrome and asthma

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 8, Issue 1, 2014, Pages 60-66

  Garmendia, Jenny V ^a   Moreno, Dolores ^a   García, Alexis H ^a   De Sanctis, Juan B ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Asthma; Dyslipidemia; Hypertension; Immune response; Insulin resistance; Metabolic syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANGIOTENSIN I; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CHEMERIN; CHEMOKINE RECEPTOR CCR2; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FETUIN; GELATINASE B; GHRELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LEPTIN; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; POTASSIUM CHANNEL; RESISTIN; RETINOL BINDING PROTEIN 4; SEX HORMONE; SUBSTANCE P; VASPIN;

ARTICLE; ASTHMA; BODY MASS; CORTICOSTEROID THERAPY; EPIDEMIOLOGICAL DATA; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LUNG DISEASE; LUNG FUNCTION; MACROPHAGE; MENARCHE; MENOPAUSE; METABOLIC SYNDROME X; MONONUCLEAR CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; VASODILATATION; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION; AGING; COMORBIDITY; IMMUNOTHERAPY; PATENT; PHYSIOLOGY;

AGING; ASTHMA; COMORBIDITY; HUMANS; IMMUNOTHERAPY; METABOLIC SYNDROME X; PATENTS AS TOPIC;

EID: 84895433435     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872214807666140107151023     Document Type: Article

References (108)

1. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: Definitions and controversies. BMC Med 2011; 9: 48.
2. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111(11): 1448-54.
3. Sovio U, Skow A, Falconer C, Park MH, Viner RM, Kinra S. Improving prediction algorithms for cardiometabolic risk in children and adolescents. J Obes 2013; 2013: 684782.
4. Yarnell JW, Patterson CC, Bainton D, Sweetnam PM. Is metabolic syndrome a discrete entity in the general population? Evidence from the Caerphilly and Speedwell population studies. Heart 1998; 79(3): 248-52.
5. Wenzel SE. Asthma phenotypes: The evolution from clinical to molecular approaches. Nat Med 2012; 18(5): 716-25.
6. O'Byrne PM. Global guidelines for asthma management: Summary of the current status and future challenges. Pol Arch Med Wewn 2010; 120(12): 511-7.
7. Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org/uploads/users/files/GINA (Accessed on: December 18, 2013).
8. van Huisstede A, Castro Cabezas M, van de Geijn GJ, Mannaerts GH, Njo TL, Taube C, et al. Under diagnosis and over diagnosis of asthma in the morbidly obese. Respir Med 2013; 107(9): 1356-64.
9. Jensen ME, Gibson PG, Collins CE, Wood LG. Airway and systemic inflammation in obese children with asthma. Eur Respir J 2013; 42(4): 1012-9.
10. Brumpton BM, Camargo CA Jr, Romundstad PR, Langhammer A, Chen Y, Mai XM. Metabolic syndrome and incidence of asthma in adults: The HUNT study. Eur Respir J 2013; 42(6): 1495-502.
11. Dandona P, Ghanim H, Monte SV, Caruana JA, Green K, Abuaysheh S, et al. Increase in the Mediators of Asthma in Obesity and Obesity with Type 2 Diabetes: Reduction with Weight Loss. Obesity (Silver Spring). 2013; Jun 26.
12. Assad N, Qualls C, Smith LJ, Arynchyn A, Thyagarajan B, Schuyler M, et al. Body mass index is a stronger predictor than the metabolic syndrome for future asthma in women. The longitudinal CARDIA study. Am J Respir Crit Care Med 2013; 188(3): 319-26.
13. Feng Y, Hong X, Wilker E, Li Z, Zhang W, Jin D, et al. Effects of age at menarche, reproductive years, and menopause on metabolic risk factors for cardiovascular diseases. Atherosclerosis 2008; 196(2): 590-7.
14. Glueck CJ, Morrison JA, Wang P, Woo JG. Early and late menarche is associated with oligomenorrhea and predict metabolic syndrome 26 years later. Metabolism 2013; 62(11): 1597-606.
15. Brumpton B, Langhammer A, Romundstad P, Chen Y, Mai XM. General and abdominal obesity and incident asthma in adults: The HUNT study. Eur Respir J 2013; 41(2): 323-9.
16. Sepe A, Tchkonia T, Thomou T, Zamboni M, Kirkland JL. Aging and regional differences in fat cell progenitors-a mini-review. Gerontology 2011; 57(1): 66-75.
17. Bremer AA, Jialal I. Adipose tissue dysfunction in nascent metabolic syndrome. J Obes 2013; 2013: 393192.
18. Staiano AE, Katzmarzyk PT. Ethnic and sex differences in body fat and visceral and subcutaneous adiposity in children and adolescents. Int J Obes (Lond) 2012; 36(10): 1261-9.
19. Blüher M. Clinical relevance of adipokines. Diabetes Met J 2012; 36: 317-27.
20. Ali Assad N, Sood A. Leptin, adiponectin and pulmonary diseases. Biochimie 2012; 94(10): 2180-9.
21. Al-Suhaimi EA, Shehzad A. Leptin, resistin and visfatin: The missing link between endocrine metabolic disorders and immunity. Eur J Med Res 2013; 18:12.
22. Vernooy JH, Ubags ND, Brusselle GG, Tavernier J, Suratt BT, Joos GF, Wouters EF, Bracke KR. Leptin as regulator of pulmonary immune responses: Involvement in respiratory diseases. Pulm Pharmacol Ther 2013; 26(4): 464-72.
23. Tsaroucha A, Daniil Z, Malli F, Georgoulias P, Minas M, Kostikas K, et al. Leptin, adiponectin, and ghrelin levels in female patients with asthma during stable and exacerbation periods. J Asthma 2013; 50(2): 188-97.
24. Chen YC, Dong GH, Lin KC, Lee YL. Gender difference of childhood overweight and obesity in predicting the risk of incident asthma: A systematic review and meta-analysis. Obes Rev 2013; 14(3): 222-31.
25. Smith MM, Minson CT. Obesity and adipokines: Effects on sympathetic over activity. J Physiol 2012; 590:1787-801.
26. Grotta MB, Squebola-Cola DM, Toro AA, Ribeiro MA, Mazon SB, Ribeiro JD, et al. Obesity increases eosinophil activity in asthmatic children and adolescents. BMC Pulm Med 2013; 13(1): 39.
27. Gowdy KM, Fessler MB. Emerging roles for cholesterol and lipoproteins in lung disease. Pulm Pharmacol Ther 2013; 26(4): 430-7.
28. Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol 2010; 126: 754e62. e1.
29. Zeki AA, Kenyon NJ, Goldkorn T. Statin drugs, metabolic pathways, and asthma: A therapeutic opportunity needing further research. Drug Metab Lett 2011; 5(1): 40-4.
30. Huang CC, Chan WL, Chen YC, Chen TJ, Chou KT, Lin SJ, et al. Statin use in patients with asthma: A nationwide population-based study. Eur J Clin Invest 2011; 41: 507-12.
31. Yuan C, Zhou L, Cheng J, Zhang J, Teng Y, Huang M, Adcock IM, et al. Statins as potential therapeutic drug for asthma? Respir Res 2012; 13:108.
32. Silva D, Couto M, Delgado L, Moreira A. A systematic review of statin efficacy in asthma. J Asthma 2012; 49(9): 885-94.
33. Moini A, Azimi G, Farivar A. Evaluation of atorvastatin for the treatment of patients with asthma: A double-blind randomized clinical trial. Allergy Asthma Immunol Res 2012; 4(5): 290-4.
34. Lokhandwala T, West-Strum D, Banahan BF, Bentley JP, Yang Y. Do statins improve outcomes in patients with asthma on inhaled corticosteroid therapy? A retrospective cohort analysis. BMJ Open 2012; 2(3): doi: 10.1136/bmjopen-2012-001279.
35. Ostroukhova M, Kouides RW, Friedman E. The effect of statin therapy on allergic patients with asthma. Ann Allergy Asthma Immunol 2009; 103: 463-8.
36. Zeki AA, Oldham J, Wilson M, Fortenko O, Goyal V, Last M, et al. Statin use and asthma control in patients with severe asthma. BMJ Open 2013; 3: e003314 doi: 10.1136/bmjopen-2013-003314.
37. Maneechotesuwan K, Kasetsinsombat K, Wamanuttajinda V, Wongkajornsilp A, Barnes PJ. Statins enhance the effects of corticosteroids on the balance between regulatory T cells and Th17 cells. Clin Exp Allergy 2013; 43(2): 212-22.
38. Capra V, Rovati GE. Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents. Pulm Pharmacol Ther 2013; pii: S1094-5539(13)00135-1.
39. Menzies D, Nair A, Meldrum KT, Fleming D, Barnes M, Lipworth BJ. Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol 2007; 119: 328e35.
40. Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR. Simvastatin in the treatment of asthma: Lack of steroid-sparing effect. Thorax 2010; 65: 891e6.
41. Si XB, Zhang S, Huo LY, Dai WL, Wang HL. Statin therapy does not improve lung function in asthma: A meta-analysis of randomized controlled trials. J Int Med Res 2013; 41(2): 276-83.
42. Agrawal A, Mabalirajan U, Ahmad T, Ghosh B. Emerging interface between metabolic syndrome and asthma. Am J Respir Cell Mol Biol 2011; 44(3): 270-5.
43. Al-Sahab B, Hamadeh MJ, Ardern CI, Tamim H. Early menarche predicts incidence of asthma in early adulthood. Am J Epidemiol 2011; 173(1): 64-70
44. Macsali F, Real FG, Plana E, Sunyer J, Anto J, Dratva J, et al. Early age at menarche, lung function, and adult asthma. Am J Respir Crit Care Med 2011; 183(1): 8-14.
45. Gnatiuc L, Kato B, Matheson MC, Newson RB, Jarvis DL. The association of asthma with BMI and menarche in the 1958 British Birth Cohort. J Asthma 2013; 50(7): 751-8.
46. Zemp E, Schikowski T, Dratva J, Schindler C, Probst-Hensch N. Asthma and the menopause: A systematic review and metaanalysis. Maturitas 2012; 73(3): 212-7.
47. Aydin M, Koca C, Ozol D, Uysal S, Yildirim Z, Kavakli HS, et al. Interaction of metabolic syndrome with asthma in postmenopausal women: Role of adipokines. Inflammation 2013; 36(6): 1232-8.
48. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: Evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86(3): 1306-12.
49. Aljada A, Ghanim H, Friedman J, Garg R, Mohanty P, Dandona P. Troglitazone reduces the expression of PPARgamma while stimulating that of PPARalpha in mononuclear cells in obese subjects. J Clin Endocrinol Metab 2001; 86(7): 3130-3.
50. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004; 89(6): 2728-35.
51. Park CS, Bang BR, Kwon HS, Moon KA, Kim TB, Lee KY, et al. Metformin reduces airway inflammation and remodeling via activation of AMP-activated protein kinase. Biochem Pharmacol 2012; 84(12): 1660-70.
52. Zhu M, Flynt L, Ghosh S, Mellema M, Banerjee A, Williams E, et al. Anti-inflammatory effects of thiazolidinediones in human airway smooth muscle cells. Am J Respir Cell Mol Biol 2011; 45(1): 111-9.
53. Menzies D, Nair A, Meldrum KT, Fleming D, Barnes M, Lipworth BJ, et al. Alendronate attenuates eosinophilic airway inflammation associated with suppression of Th2 cytokines, Th17 cytokines, and eotaxin-2. J Immunol 2013; 191(6): 2879-89.
54. Wu J, Zhang Y, Liu Q, Zhong W, Xia Z. All-trans retinoic acid attenuates airway inflammation by inhibiting Th2 and Th17 response in experimental allergic asthma. BMC Immunol 2013; 14: 28.
55. Tsuchiya H, Ikeda Y, Ebata Y, Kojima C, Katsuma R, Tsuruyama T, et al. Retinoids ameliorate insulin resistance in a leptindependent manner in mice. Hepatology 2012; 56(4): 1319-30.
56. Mcilroy GD, Delibegovic M, Owen C, Stoney PN, Shearer KD, McCaffery PJ, et al. Fenretinide treatment prevents diet-induced obesity in association with major alterations in retinoid homeostatic gene expression in adipose, liver, and hypothalamus. Diabetes 2013; 62(3): 825-36.
57. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitorinduced cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 169S-73S.
58. Self TH, Wallace JL, Soberman JE. Cardioselective beta-blocker treatment of hypertension in patients with asthma: When do benefits outweigh risks? J Asthma 2012; 49(9): 947-51.
59. Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma. Am J Respir Crit Care Med 2013; 187(12): 1308-14.
60. Pelletier L, Guéry JC. Dihydropyridine receptor blockade in the treatment of asthma. Recent Pat Inflamm Allergy Drug Discov 2008; 2(2): 109-16.
61. Valverde MA, Cantero-Recasens G, Garcia-Elias A, Jung C, Carreras-Sureda A, Vicente R. Ion channels in asthma. J Biol Chem 2011; 286(38): 32877-82.
62. Bradding P, Wulff H. The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy. Br J Pharmacol 2009; 157(8): 1330-9.
63. Wulff H, Castle NA. Therapeutic potential of KCa3.1 blockers: Recent advances and promising trends. Expert Rev Clin Pharmacol 2010; 3(3): 385-96.
64. Guerrero-Romero F, Rodriguez-Moran M. Serum magnesium in the metabolically-obese normal-weight and healthy-obese subjects. Eur J Intern Med 2013; 24(7): 639-43.
65. Hata A, Doi Y, Ninomiya T, Mukai N, Hirakawa Y, Hata J, et al. Magnesium intake decreases Type 2 diabetes risk through the improvement of insulin resistance and inflammation: The Hisayama Study. Diabet Med 2013; 30(12): 1487-94.
66. Shan Z, Rong Y, Yang W, Wang D, Yao P, Xie J, et al. Intravenous and nebulized magnesium sulfate for treating acute asthma in adults and children: A systematic review and meta-analysis. Respir Med 2013; 107(3): 321-30.
67. Coyle TB, Metersky ML. The effect of the endothelin-1 receptor antagonist, bosentan, on patients with poorly controlled asthma: A 17-week, double-blind, placebo-controlled crossover pilot study. J Asthma 2013; 50(4): 433-7.
68. Yalcin AD, Cilli A, Bisgin A, Strauss LG, Herth F. Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels. Expert Opin Biol Ther 2013; 13(9): 1335-41.
69. Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taillé C, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 2013; 144(2): 411-9.
70. Lommatzsch M, Korn S, Buhl R, Virchow JC. Against all odds: Anti-IgE for intrinsic asthma? Thorax 2013; doi: 10.1136/thoraxjnl-2013-203738.
71. Arron JR, Scheerens H, Matthews JG. Redefining approaches to asthma: Developing targeted biologic therapies. Adv Pharmacol 2013; 66: 1-49.
72. Garcia G, Taillé C, Laveneziana P, Bourdin A, Chanez P, Humbert M. Anti-interleukin-5 therapy in severe asthma. Eur Respir Rev 20131; 22(129): 251-7.
73. Taillé C, Poulet C, Marchand-Adam S, Borie R, Dombret MC, Crestani B, et al. Monoclonal anti-TNF--antibodies for severe steroid-dependent asthma: A case series. Open Respir Med J 2013; 7: 21-5.
74. Guilleminault L, Carré P, Beau-Salinas F, Taillé C, Dieudé P, Crestani B, et al. Asthma unmasked with tumor necrosis factor---blocking drugs. Chest 2011; 140(4): 1068-71.
75. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 2012; 14(3): R141.
76. Ferraz-Amaro I, Arce-Franco M, Muñiz J, López-Fernández J, Hernández-Hernández V, Franco A, et al. Systemic blockade of TNF--does not improve insulin resistance in humans. Horm Metab Res 2011; 43(11): 801-8.
77. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J. Insulin resistance in rheumatoid arthritis: The impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci 2010; 1193: 153-9.
78. Catley MC, Coote J, Bari M, Tomlinson KI. Monoclonal antibodies for the treatment of asthma. Pharmacol Therap 2011; 132: 333-51.
79. Ota T. Chemokine systems link obesity to insulin resistance. Diabetes Metab J 2013; 37(3): 165-72.
80. Malagón MM, Díaz-Ruiz A, Guzmán-Ruiz R, Jiménez-Gómez Y, Moreno NR, García-Navarro S, et al. Adipobiology for novel therapeutic approaches in metabolic syndrome. Curr Vasc Pharmacol 2013; [Epub ahead of print].
81. Srinivasan V, Ohta Y, Espino J, Pariente JA, Rodriguez AB, Mohamed M, et al. Metabolic syndrome, its pathophysiology and the role of melatonin. Recent Pat Endocr Metab Immune Drug Discov 2013; 7(1): 11-25.
82. Raval SK, Raval PS, Jain MR. Emerging therapies for dyslipidemia: Known knowns and known unknowns of MTP inhibitors. Recent Pat Endocr Metab Immune Drug Discov 2012; 6(1): 24-9.
83. Cosenso-Martin LN, Vilela-Martin JF. Is there an association between vitamin D and hypertension? Recent Pat Cardiovasc Drug Discov 2011; 6(2): 140-7.
84. Łazewska D, Kieć-Kononowicz K. Recent advances in histamine H3 receptor antagonists/inverse agonists. Expert Opin Ther Pat 2010; 20(9): 1147-69.
85. Boyle CD, Kowalski TJ. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: A review of recent patents. Expert Opin Ther Pat 2009; 19(6): 801-25.
86. Naik SR, Wala SM. Inflammation, allergy and asthma, complex immune origin diseases: Mechanisms and therapeutic agents. Recent Pat Inflamm Allergy Drug Discov 2013; 7(1): 62-95.
87. Kiss R, Keseru{double acute} GM. Histamine H4 receptor ligands and their potential therapeutic applications: An update. Expert Opin Ther Pat 2012; 22(3): 205-21.
88. El-Qutob López D. New methods of prevention and treatment of allergic diseases. Recent Pat Inflamm Allergy Drug Discov 2012; 6(1): 46-64.
89. Samitas K, Rådinger M, Bossios A. Current update on eosinophilic lung diseases and anti-IL-5 treatment. Recent Pat Antiinfect Drug Discov 2011; 6(3): 189-205.
90. Larocca NE, Moreno D, Garmendia JV, De Sanctis JB. Role of beta2 agonists inrespiratory medicine with particular attention to novel patents and effects on endocrine system and immune response. Recent Pat Endocr Metab Immune Drug Discov 2011; 5(3): 230-6.
91. Joks R, Durkin HG. Effect of tetracyclines on IgE allergic responses and asthma. Recent Pat Inflamm Allergy Drug Discov 2011; 5(3): 221-8.
92. Gras D, Chanez P, Vachier I, Petit A, Bourdin A. Bronchial epithelium as a target for innovative treatments in asthma. Pharmacol Ther 2013; 140(3): 290-305.
93. Zuo L, Otenbaker NP, Rose BA, Salisbury KS. Molecular mechanisms of reactive oxygen species-related pulmonary inflammation and asthma. Mol Immunol 2013; 56(1-2): 57-63.
94. Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, et al. An inhibitor of the protein kinases TBK1 and IKK-ε improves obesity-related metabolic dysfunctions in mice. Nat Med 2013; 19(3): 313-21.
95. Koch L. Obesity: Teaching an old drug new trick--amlexanox targets inflammation to improve metabolic dysfunction. Nat Rev Endocrinol 2013; 9(4): 185. doi:10.1038/nrendo.2013.42.
96. Nohara, A. Amino-5-oxo-5H-[1]benzopyrano[2,3-b]pyridine-3-carboxylic acid derivatives and their production. US4716167 (1986).
97. Saijo T, Makino H, Tamura S, Kuriki H, Ashida Y, Terao S, Maki Y. The antiallergic agent amoxanox suppresses SRS-A generation by inhibiting lipoxygenase. Int Arch Allergy Appl Immunol 1986; 79(3): 231-7.
98. Vora, K.R., Khandwala, A., Smith, C.G. Methods of treating aphthous ulcers and other mucocutaneous disorders with amlexanox. US5362737 (1994).
99. Thongprasom K, Prapinjumrune C, Carrozzo M. Novel therapies for oral lichen planus. J Oral Pathol Med 2013; doi: 10.1111/jop.12083.
100. Saltien, A.R., Decker, S. Compositions and methods for the treatment of obesity and related disorders. US20120208836 (2012).
101. Boulares, H.A., Hans, C.P., Naura, A.S. Regression of established atherosclerotic plaques, and treating sudden-onset asthma attacks, using PARP Inhibitors. US20110028420 (2011).
102. Sorensen, A., Meyer, J.P., Alberts, P., Prathama, M.S., Crameri, M.H., Bonnaud, T., Kelleher, J., Pearson, D. Substituted 1,3-dioxanes useful as PPAR modulators. US20130267561 (2013).
103. Fernandez-Boyanapalli R, Goleva E, Kolakowski C, Min E, Day B, Leung DY, et al. Obesity impairs apoptotic cell clearance in asthma. J Allergy Clin Immunol 2013; 131(4): 1041-7.
104. Ilmarinen P, Kankaanranta H. Eosinophil apoptosis as a therapeutic target in allergic asthma. Basic Clin Pharmacol Toxicol 2013; doi: 10.1111/bcpt.12163.
105. Peña MJ, De Sanctis JB. Recent patents in autophagy and immune response. Recent Pat Inflamm Allergy Drug Discov 2013; 7(3): 215-22.
106. Buyan, R.D. Treatment of obesity and obesity related disorders by pharmacological targeting Kv1.3 potassium channels. WO2013052507 (2013).
107. Hwang, I.S. Pyrimidine-2, 4-diamine Jak2 kinase inhibiting antiinflammation use. WO2010011349 (2013).
108. Penas-Steinhardt A, Tellechea ML, Gomez-Rosso L, Brites F, Frechtel GD, Poskus E. Association of common variants in JAK2 gene with reduced risk of metabolic syndrome and related disorders. BMC Med Genet 2011; 12: 166.